Octamer-binding transcription factors: Genomics and functions

Frontiers in Bioscience

Volumn 18, Issue 3, 2013, Pages 1051-1071

  Zhao, Feng Qi ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Genomic organization; Oct1; Oct2; Oct4; Review; Transcription factor

Indexed keywords

EID: 84880519793     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4162     Document Type: Article

References (197)

1. J. T. Kadonaga: Regulation of RNA polymerase II transcription by sequence-specific DNA binding factors. Cell 116, 247-257 (2004). (Pubitemid 38173000)
2. F. Q. Zhao, Y. Zheng, B. Dong and T. Oka: Cloning, genomic organization, expression, and effect on beta-casein promoter activity of a novel isoform of the mouse Oct-1 transcription factor. Gene 326, 175-187 (2004). (Pubitemid 38068499)
3. H. R. Scholer, A. K. Hatzopoulos, R. Balling, N. Suzuki and P. Gruss: A family of octamer-specific proteins present during mouse embryogenesis: evidence for germlinespecific expression of an Oct factor. EMBO J 8, 2543-2550 (1989). (Pubitemid 19273337)
4. H. R. Scholer: Octamania: The POU factors in murine development. Trends Genet 7, 323-329 (1991). (Pubitemid 121002136)
5. A. S. Goldsborough, L. E. Healy, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, K. R. Willison and A. Ashworth: Cloning, chromosomal localization and expression pattern of the POU domain gene Oct-11. Nucleic Acids Res 21, 127-134 (1993). (Pubitemid 23146302)
6. R. A. Sturm, G. Das and W. Herr: The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain. Genes Dev 2, 1582-1599 (1988).
7. R. G. Clerc, L. M. Corcoran, J. H. LeBowitz, D. Baltimore and P. A. Sharp: The B-cell-specific Oct-2 protein contains POU box- and homeo box-type domains. Genes Dev 2, 1570-1581 (1988).
8. M. H. Rosner, M. A. Vigano, K. Ozato, P. M. Timmons, F. Poirier, P. W. Rigby and L. M. Staudt: A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature 345, 686-692 (1990).
9. D. Meijer, A. Graus, R. Kraay, A. Langeveld, M. P. Mulder and G. Grosveld: The octamer binding factor Oct6: cDNA cloning and expression in early embryonic cells. Nucleic Acids Res 18, 7357-7365 (1990). (Pubitemid 120006038)
10. S. Atanasoski, S. S. Toldo, U. Malipiero, E. Schreiber, R. Fries and A. Fontana: Isolation of the human genomic brain-2/N-Oct 3 gene (POUF3) and assignment to chromosome 6q16. Genomics 26, 272-280 (1995).
11. E. Schreiber, A. Tobler, U. Malipiero, W. Schaffner and A. Fontana: cDNA cloning of human N-Oct3, a nervous-system specific POU domain transcription factor binding to the octamer DNA motif. Nucleic Acids Res 21, 253-258 (1993). (Pubitemid 23151895)
12. X. He, M. N. Treacy, D. M. Simmons, H. A. Ingraham, L. W. Swanson and M. G. Rosenfeld: Expression of a large family of POU-domain regulatory genes in mammalian brain development. Nature 340, 35-41 (1989).
13. P. J. Douville, S. Atanasoski, A. Tobler, A. Fontana and M. E. Schwab: The brain-specific POU-box gene Brn4 is a sex-linked transcription factor located on the human and mouse X chromosomes. Mamm Genome 5, 180-182 (1994). (Pubitemid 2077957)
14. B. Dong and F. Q. Zhao: Expression of the Oct-2 transcription factor in mouse mammary gland and cloning and characterization of a novel Oct-2 isoform. Cell Tissue Res 328, 595-606 (2007). (Pubitemid 46684498)
15. G. J. Veenstra, P. C. van der Vliet and O. H. Destree: POU domain transcription factors in embryonic development. Mol Biol Rep 24, 139-155 (1997). (Pubitemid 27358368)
16. D. S. Latchman: POU family transcription factors in the nervous system. J Cell Physiol 179, 126-133 (1999). (Pubitemid 29165140)
17. C. P. Verrijzer and P. C. Van der Vliet: POU domain transcription factors. Biochim Biophys Acta 1173, 1-21 (1993). (Pubitemid 23125489)
18. K. L. Christensen, A. N. Patrick, E. L. McCoy and H. L. Ford: The six family of homeobox genes in development and cancer. Adv Cancer Res 101, 93-126 (2008).
19. C. Wolberger: Homeodomain interactions. Curr Opin Struct Biol 6, 62-68 (1996). (Pubitemid 26073945)
20. W. Herr, R. A. Sturm, R. G. Clerc, L. M. Corcoran, D. Baltimore, P. A. Sharp, H. A. Ingraham, M. G. Rosenfeld, M. Finney, G. Ruvkun and et al.: The POU domain: A large conserved region in the mammalian pit-1, oct-1, oct-2, and Caenorhabditis elegans unc-86 gene products. Genes Dev 2, 1513-1516 (1988).
21. C. P. Verrijzer, M. J. Alkema, W. W. van Weperen, H. C. Van Leeuwen, M. J. Strating and P. C. van der Vliet: The DNA binding specificity of the bipartite POU domain and its subdomains. EMBO J 11, 4993-5003 (1992). (Pubitemid 23023443)
22. M. D. Schonemann, A. K. Ryan, L. Erkman, R. J. McEvilly, J. Bermingham and M. G. Rosenfeld: POU domain factors in neural development. Adv Exp Med Biol 449, 39-53 (1998). (Pubitemid 28566367)
23. N. Dekker, M. Cox, R. Boelens, C. P. Verrijzer, P. C. van der Vliet and R. Kaptein: Solution structure of the POUspecific DNA-binding domain of Oct-1. Nature 362, 852-855 (1993). (Pubitemid 23132163)
24. M. C. Botfield, A. Jancso and M. A. Weiss: Biochemical characterization of the Oct-2 POU domain with implications for bipartite DNA recognition. Biochemistry 31, 5841-5848 (1992).
25. J. W. Voss, L. Wilson and M. G. Rosenfeld: POU-domain proteins Pit-1 and Oct-1 interact to form a heteromeric complex and can cooperate to induce expression of the prolactin promoter. Genes Dev 5, 1309-1320 (1991). (Pubitemid 21906040)
26. S. Inamoto, N. Segil, Z. Q. Pan, M. Kimura and R. G. Roeder: The cyclin-dependent kinase-activating kinase (CAK) assembly factor, MAT1, targets and enhances CAK activity on the POU domains of octamer transcription factors. J Biol Chem 272, 29852-29858 (1997). (Pubitemid 27508083)
27. G. G. Prefontaine, R. Walther, W. Giffin, M. E. Lemieux, L. Pope and R. J. Hache: Selective binding of steroid hormone receptors to octamer transcription factors determines transcriptional synergism at the mouse mammary tumor virus promoter. J Biol Chem 274, 26713-26719 (1999).
28. J. S. Lai, M. A. Cleary and W. Herr: A single amino acid exchange transfers VP16-induced positive control from the Oct-1 to the Oct-2 homeo domain. Genes Dev 6, 2058-2065 (1992).
29. M. Tanaka, J. S. Lai and W. Herr: Promoter-selective activation domains in Oct-1 and Oct-2 direct differential activation of an snRNA and mRNA promoter. Cell 68, 755- 767 (1992).
30. G. J. Veenstra, J. Peterson-Maduro, M. T. Mathu, P. C. van der Vliet and O. H. Destree: Non-cell autonomous induction of apoptosis and loss of posterior structures by activation domainspecific interactions of Oct-1 in the Xenopus embryo. Cell Death Differ 5, 774-784 (1998). (Pubitemid 28439118)
31. B. Dong and F. Q. Zhao: Involvement of the ubiquitous Oct-1 transcription factor in hormonal induction of beta-casein gene expression. Biochem J 401, 57-64 (2007). (Pubitemid 46114599)
32. M. Tanaka and W. Herr: Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell 60, 375-386 (1990).
33. K. A. Lillycrop, S. J. Dawson, J. K. Estridge, T. Gerster, P. Matthias and D. S. Latchman: Repression of a herpes simplex virus immediate-early promoter by the Oct-2 transcription factor is dependent on an inhibitory region at the N terminus of the protein. Mol Cell Biol 14, 7633-7642 (1994).
34. L. M. Corcoran, F. Koentgen, W. Dietrich, M. Veale and P. O. Humbert: All known in vivo functions of the Oct-2 transcription factor require the C-terminal protein domain. J Immunol 172, 2962-2969 (2004). (Pubitemid 38263683)
35. A. Brehm, K. Ohbo and H. Scholer: The carboxy-terminal transactivation domain of Oct-4 acquires cell specificity through the POU domain. Mol Cell Biol 17, 154-162 (1997). (Pubitemid 26425604)
36. M. Imagawa, A. Miyamoto, M. Shirakawa, H. Hamada and M. Muramatsu: Stringent integrity requirements for both trans-activation and DNA-binding in a trans-activator, Oct3. Nucleic Acids Res 19, 4503-4508 (1991). (Pubitemid 21912831)
37. K. Phillips and B. Luisi: The virtuoso of versatility: POU proteins that flex to fit. J Mol Biol 302, 1023-1039 (2000).
38. Y. Takayama and G. M. Clore: Intra- and intermolecular translocation of the bi-domain transcription factor Oct1 characterized by liquid crystal and paramagnetic NMR. Proc Natl Acad Sci U S A 108, E169-E176 (2011).
39. Y. Takayama and G. M. Clore: Interplay between minor and major groove-binding transcription factors Sox2 and Oct1 in translocation on DNA studied by paramagnetic and diamagnetic NMR. J Biol Chem 287, 14349-14363 (2012).
40. R. Aurora and W. Herr: Segments of the POU domain influence one another's DNA-binding specificity. Mol Cell Biol 12, 455-467 (1992).
41. H. C. van Leeuwen, M. J. Strating, M. Rensen, W. de Laat and P. C. van der Vliet: Linker length and composition influence the flexibility of Oct-1 DNA binding. EMBO J 16, 2043-2053 (1997). (Pubitemid 27170965)
42. X. F. Fang, W. Y. Zhang, N. Zhao, W. Yu, D. Ding, X. Hong, L. S. Li, H. R. Zhang, S. Zheng and B. Y. Lin: Genome-wide analysis of OCT4 binding sites in glioblastoma cancer cells. J Zhejiang Univ Sci B 12, 812- 819 (2011).
43. N. Segil, S. B. Roberts and N. Heintz: Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA binding activity. Science 254, 1814-1816 (1991). (Pubitemid 21917536)
44. N. Segil, S. B. Roberts and N. Heintz: Cell-cycleregulated phosphorylation of the transcription factor Oct-1. Cold Spring Harb Symp Quant Biol 56, 285-292 (1991).
45. S. J. Grenfell, D. S. Latchman and N. S. Thomas: Oct-1 [corrected] and Oct-2 DNA-binding site specificity is regulated in vitro by different kinases. Biochem J 315 ( Pt 3), 889-893 (1996).
46. I. Ahmad, D. C. Hoessli, E. Walker-Nasir, S. M. Rafik, A. R. Shakoori and D. Nasirud: Oct-2 DNA binding transcription factor: functional consequences of phosphorylation and glycosylation. Nucl. Acids Res. 34, 175-184 (2006). (Pubitemid 43167921)
47. A. G. Smith, G. Brightwell, S. E. Smit, P. G. Parsons and R. A. Sturm: Redox regulation of Brn-2/N-Oct-3 POU domain DNA binding activity and proteolytic formation of N-Oct-5 during melanoma cell nuclear extraction. Melanoma Res 8, 2-10 (1998). (Pubitemid 28114295)
48. F. Wei, H. R. Scholer and M. L. Atchison: Sumoylation of Oct4 enhances its stability, DNA binding, and transactivation. J Biol Chem 282, 21551-21560 (2007). (Pubitemid 47099909)
49. F. La Bella, P. Gallinari, J. McKinney and N. Heintz: Histone H1 subtype-specific consensus elements mediate cell cycle-regulated transcription in vitro. Genes Dev 3, 1982-1990 (1989). (Pubitemid 20023222)
50. F. LaBella, H. L. Sive, R. G. Roeder and N. Heintz: Cell-cycle regulation of a human histone H2b gene is mediated by the H2b subtype-specific consensus element. Genes Dev 2, 32-39 (1988).
51. M. Dreyfus, N. Doyen and F. Rougeon: The conserved decanucleotide from the immunoglobulin heavy chain promoter induces a very high transcriptional activity in Bcells when introduced into an heterologous promoter. EMBO J 6, 1685-1690 (1987).
52. T. Wirth, L. Staudt and D. Baltimore: An octamer oligonucleotide upstream of a TATA motif is sufficient for lymphoid-specific promoter activity. Nature 329, 174-178 (1987). (Pubitemid 17125258)
53. F. Q. Zhao, K. Adachi and T. Oka: Involvement of Oct- 1 in transcriptional regulation of beta-casein gene expression in mouse mammary gland. Biochim Biophys Acta 1577, 27-37 (2002). (Pubitemid 34876601)
54. M. H. Kim and D. O. Peterson: Stimulation of basal transcription from the mouse mammary tumor virus promoter by Oct proteins. J. Virol. 69, 4717-4726 (1995).
55. Y. Z. Liu and D. S. Latchman: The octamer-binding proteins Oct-1 and Oct-2 repress the HIV long terminal repeat promoter and its transactivation by Tat. Biochem J 322 ( Pt 1), 155-158 (1997).
56. S. Stern, M. Tanaka and W. Herr: The Oct-1 homoeodomain directs formation of a multiprotein-DNA complex with the HSV transactivator VP16. Nature 341, 624-630 (1989). (Pubitemid 19257310)
57. M. Gstaiger, L. Knoepfel, O. Georgiev, W. Schaffner and C. M. Hovens: A B-cell coactivator of octamer-binding transcription factors. Nature 373, 360-362 (1995).
58. L. Lee, E. Stollar, J. Chang, J. G. Grossmann, R. O'Brien, J. Ladbury, B. Carpenter, S. Roberts and B. Luisi: Expression of the Oct-1 transcription factor and characterization of its interactions with the Bob1 coactivator. Biochemistry 40, 6580-6588 (2001). (Pubitemid 32552783)
59. R. A. Sturm, J. L. Cassady, G. Das, A. Romo and G. A. Evans: Chromosomal structure and expression of the human OTF1 locus encoding the Oct-1 protein. Genomics 16, 333-341 (1993). (Pubitemid 23170886)
60. E. V. Pankratova, I. E. Deyev, S. V. Zhenilo and O. L. Polanovsky: Tissue-specific isoforms of the ubiquitous transcription factor Oct-1. Mol Genet Genomics 266, 239- 245 (2001). (Pubitemid 32938418)
61. A. K. Hatzopoulos, A. S. Stoykova, J. R. Erselius, M. Goulding, T. Neuman and P. Gruss: Structure and expression of the mouse Oct2a and Oct2b, two differentially spliced products of the same gene. Development 109, 349-362 (1990). (Pubitemid 20205575)
62. T. Wirth, A. Priess, A. Annweiler, S. Zwilling and B. Oeler: Multiple Oct2 isoforms are generated by alternative splicing. Nucleic Acids Res 19, 43-51 (1991).
63. D. S. Latchman: The Oct-2 transcription factor. Int J Biochem Cell Biol 28, 1081-1083 (1996). (Pubitemid 26361884)
64. K. A. Lillycrop and D. S. Latchman: Alternative splicing of the Oct-2 transcription factor RNA is differentially regulated in neuronal cells and B cells and results in protein isoforms with opposite effects on the activity of octamer/TAATGARAT-containing promoters. J Biol Chem 267, 24960-24965 (1992).
65. L. M. Corcoran, M. Karvelas, G. J. Nossal, Z. S. Ye, T. Jacks and D. Baltimore: Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival. Genes Dev 7, 570- 582 (1993). (Pubitemid 23125258)
66. K. Schubart, S. Massa, D. Schubart, L. M. Corcoran, A. G. Rolink and P. Matthias: B cell development and immunoglobulin gene transcription in the absence of Oct-2 and OBF-1. Nat Immunol 2, 69-74 (2001). (Pubitemid 33704956)
67. M. Pesce and H. R. Scholer: Oct-4: control of totipotency and germline determination. Mol Reprod Dev 55, 452-457 (2000). (Pubitemid 30137108)
68. M. Tai, C. Chang, L. Olson and J. Trosko: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26, 495-502 (2005). (Pubitemid 40246573)
69. J. Takeda, S. Seino and G. I. Bell: Human Oct3 gene family: cDNA sequences, alternative splicing, gene organization, chromosomal location, and expression at low levels in adult tissues. Nucleic Acids Res 20, 4613-4620 (1992).
70. Y. Atlasi, S. J. Mowla, S. A. Ziaee, P. J. Gokhale and P. W. Andrews: OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells 26, 3068-3074 (2008).
71. J. Lee, H. K. Kim, J. Y. Rho, Y. M. Han and J. Kim: The human OCT-4 isoforms differ in their ability to confer self-renewal. J Biol Chem 281, 33554-33565 (2006). (Pubitemid 46036736)
72. X. Wang, Y. Zhao, Z. Xiao, B. Chen, Z. Wei, B. Wang, J. Zhang, J. Han, Y. Gao, L. Li, H. Zhao, W. Zhao, H. Lin and J. Dai: Alternative translation of OCT4 by an internal ribosome entry site and its novel function in stress response. Stem Cells 27, 1265-1275 (2009).
73. S. Kastler, L. Honold, M. Luedeke, R. Kuefer, P. Moller, J. Hoegel, W. Vogel, C. Maier and G. Assum: POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. Prostate 70, 666-674 (2010).
74. S. Zhao, Q. Yuan, H. Hao, Y. Guo, S. Liu, Y. Zhang, J. Wang, H. Liu, F. Wang, K. Liu, E. A. Ling and A. Hao: Expression of OCT4 pseudogenes in human tumours: lessons from glioma and breast carcinoma. J Pathol 223, 672-682 (2011).
75. D. Pain, G. W. Chirn, C. Strassel and D. M. Kemp: Multiple retropseudogenes from pluripotent cell-specific gene expression indicates a potential signature for novel gene identification. J Biol Chem 280, 6265-6268 (2005). (Pubitemid 40347250)
76. G. Suo, J. Han, X. Wang, J. Zhang, Y. Zhao and J. Dai: Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun 337, 1047-1051 (2005). (Pubitemid 41505231)
77. X. Guo and Y. Tang: OCT4 pseudogenes present in human leukemia cells. Clin Exp Med (2011).
78. E. S. Monuki, R. Kuhn, G. Weinmaster, B. D. Trapp and G. Lemke: Expression and activity of the POU transcription factor SCIP. Science 249, 1300-1303 (1990).
79. N. Suzuki, H. Rohdewohld, T. Neuman, P. Gruss and H. R. Scholer: Oct-6: A POU transcription factor expressed in embryonal stem cells and in the developing brain. EMBO J 9, 3723-3732 (1990).
80. I. Faus, H. J. Hsu and E. Fuchs: Oct-6: A regulator of keratinocyte gene expression in stratified squamous epithelia. Mol Cell Biol 14, 3263-3275 (1994). (Pubitemid 24132739)
81. E. J. Ryu, J. Y. Wang, N. Le, R. H. Baloh, J. A. Gustin, R. E. Schmidt and J. Milbrandt: Misexpression of Pou3f1 results in peripheral nerve hypomyelination and axonal loss. J Neurosci 27, 11552-11559 (2007). (Pubitemid 350006899)
82. M. Ilia: Oct-6 transcription factor. Int Rev Neurobiol 59, 471-489 (2004). (Pubitemid 39752425)
83. M. Jaegle, W. Mandemakers, L. Broos, R. Zwart, A. Karis, P. Visser, F. Grosveld and D. Meijer: The POU factor Oct-6 and Schwann cell differentiation. Science 273, 507-510 (1996). (Pubitemid 26286453)
84. B. Andersen, W. C. Weinberg, O. Rennekampff, R. J. McEvilly, J. R. Bermingham Jr., F. Hooshmand, V. Vasilyev, J. F. Hansbrough, M. R. Pittelkow, S. H. Yuspa and M. G. Rosenfeld: Functions of the POU domain genes Skn-1a/i and Tst-1/Oct-6/SCIP in epidermal differentiation. Genes Dev 11, 1873-1884 (1997). (Pubitemid 27315216)
85. X. Wu, J. M. Oatley, M. J. Oatley, A. V. Kaucher, M. R. Avarbock and R. L. Brinster: The POU domain transcription factor POU3F1 is an important intrinsic regulator of GDNF-induced survival and self-renewal of mouse spermatogonial stem cells. Biol Reprod 82, 1103- 1111 (2010).
86. T. Eisen, D. J. Easty, D. C. Bennett and C. R. Goding: The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene 11, 2157- 2164 (1995).
87. K. Lefort, J. P. Rouault, L. Tondereau, J. P. Magaud and J. F. Dore: The specific activation of gadd45 following UVB radiation requires the POU family gene product Noct3 in human melanoma cells. Oncogene 20, 7375-7385 (2001). (Pubitemid 33078208)
88. J. Goodall, S. Carreira, L. Denat, D. Kobi, I. Davidson, P. Nuciforo, R. A. Sturm, L. Larue and C. R. Goding: Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res 68, 7788-7794 (2008).
89. K. Sumiyama, K. Washio-Watanabe, N. Saitou, T. Hayakawa and S. Ueda: Class III POU genes: generation of homopolymeric amino acid repeats under GC pressure in mammals. J Mol Evol 43, 170-178 (1996). (Pubitemid 26315118)
90. S. Nakai, Y. Sugitani, H. Sato, S. Ito, Y. Miura, M. Ogawa, M. Nishi, K. Jishage, O. Minowa and T. Noda: Crucial roles of Brn1 in distal tubule formation and function in mouse kidney. Development 130, 4751-4759 (2003). (Pubitemid 37279426)
91. R. P. Friedrich, B. Schlierf, E. R. Tamm, M. R. Bosl and M. Wegner: The class III POU domain protein Brn-1 can fully replace the related Oct-6 during schwann cell development and myelination. Mol Cell Biol 25, 1821-1829 (2005). (Pubitemid 40280147)
92. M. Wolf, P. Lommes, E. Sock, S. Reiprich, R. P. Friedrich, J. Kriesch, C. C. Stolt, J. R. Bermingham Jr. and M. Wegner: Replacement of related POU transcription factors leads to severe defects in mouse forebrain development. Dev Biol 332, 418-428 (2009).
93. J. M. Mathis, D. M. Simmons, X. He, L. W. Swanson and M. G. Rosenfeld: Brain 4: A novel mammalian POU domain transcription factor exhibiting restricted brain-specific expression. EMBO J 11, 2551-2561 (1992).
94. X. F. Tan, J. B. Qin, G. H. Jin, M. L. Tian, H. M. Li, H. X. Zhu, X. H. Zhang, J. H. Shi and Z. Huang: Effects of Brn-4 on the neuronal differentiation of neural stem cells derived from rat midbrain. Cell Biol Int 34, 877-882 (2010).
95. E. M. Braunstein, E. B. Crenshaw 3rd, B. E. Morrow and J. C. Adams: Cooperative function of Tbx1 and Brn4 in the periotic mesenchyme is necessary for cochlea formation. J Assoc Res Otolaryngol 9, 33-43 (2008).
96. Y. J. de Kok, S. M. van der Maarel, M. Bitner-Glindzicz, I. Huber, A. P. Monaco, S. Malcolm, M. E. Pembrey, H. H. Ropers and F. P. Cremers: Association between X-linked mixed deafness and mutations in the POU domain gene POU3F4. Science 267, 685-688 (1995).
97. Y. J. de Kok, C. W. Cremers, H. H. Ropers and F. P. Cremers: The molecular basis of X-linked deafness type 3 (DFN3) in two sporadic cases: identification of a somatic mosaicism for a POU3F4 missense mutation. Hum Mutat 10, 207-211 (1997). (Pubitemid 27371678)
98. J. Li, J. Cheng, Y. Lu, A. Chen, Y. Sun, D. Kang, X. Zhang, P. Dai, D. Han and H. Yuan: Identification of a novel mutation in POU3F4 for prenatal diagnosis in a Chinese family with X-linked nonsyndromic hearing loss. J Genet Genomics 37, 787-793 (2010).
99. A. Cabral, D. F. Fischer, W. P. Vermeij and C. Backendorf: Distinct functional interactions of human Skn- 1 isoforms with Ese-1 during keratinocyte terminal differentiation. J Biol Chem 278, 17792-17799 (2003). (Pubitemid 36799383)
100. K. Nakajima, K. Tamai, T. Yamazaki, Y. Toyomaki, H. Nakano, J. Uitto and D. Sawamura: Identification of Skn-1n, a splice variant induced by high calcium concentration and specifically expressed in normal human keratinocytes. J Invest Dermatol 128, 1336-1339 (2008). (Pubitemid 351543192)
101. J. Hildesheim, R. A. Foster, M. E. Chamberlin and J. C. Vogel: Characterization of the regulatory domains of the human skn-1a/Epoc-1/Oct-11 POU transcription factor. J Biol Chem 274, 26399-26406 (1999).
102. H. Takemoto, K. Tamai, E. Akasaka, D. Rokunohe, N. Takiyoshi, N. Umegaki, K. Nakajima, T. Aizu, T. Kaneko, H. Nakano and D. Sawamura: Relation between the expression levels of the POU transcription factors Skn-1a and Skn-1n and keratinocyte differentiation. J Dermatol Sci 60, 203-205 (2010).
103. I. Matsumoto, M. Ohmoto, M. Narukawa, Y. Yoshihara and K. Abe: Skn-1a (Pou2f3) specifies taste receptor cell lineage. Nat Neurosci 14, 685-687 (2011).
104. V. E. Wang, T. Schmidt, J. Chen, P. A. Sharp and D. Tantin: Embryonic lethality, decreased erythropoiesis, and defective octamer-dependent promoter activation in Oct-1- deficient mice. Mol Cell Biol 24, 1022-1032 (2004). (Pubitemid 38112167)
105. V. E. Wang, D. Tantin, J. Chen and P. A. Sharp: B cell development and immunoglobulin transcription in Oct-1- deficient mice. Proc Natl Acad Sci U S A 101, 2005-2010 (2004). (Pubitemid 38229005)
106. V. Sebastiano, M. Dalvai, L. Gentile, K. Schubart, J. Sutter, G. M. Wu, N. Tapia, D. Esch, J. Y. Ju, K. Hubner, M. J. Bravo, H. R. Scholer, F. Cavaleri and P. Matthias: Oct1 regulates trophoblast development during early mouse embryogenesis. Development 137, 3551-3560 (2010).
107. J. Nichols, B. Zevnik, K. Anastassiadis, H. Niwa, D. Klewe-Nebenius, I. Chambers, H. Scholer and A. Smith: Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95, 379-391 (1998). (Pubitemid 28507326)
108. M. Pesce and H. R. Scholer: Oct-4: Gatekeeper in the Beginnings of Mammalian Development. Stem Cells 19, 271-278 (2001). (Pubitemid 32721093)
109. S. Nakai, H. Kawano, T. Yudate, M. Nishi, J. Kuno, A. Nagata, K. Jishage, H. Hamada, H. FujII, K. Kawamura and et al.: The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev 9, 3109-3121 (1995). (Pubitemid 26018144)
110. H. Zaehres, M. W. Lensch, L. Daheron, S. A. Stewart, J. Itskovitz-Eldor and G. Q. Daley: High-efficiency RNA interference in human embryonic stem cells. Stem Cells 23, 299-305 (2005). (Pubitemid 40404448)
111. K. Takahashi and S. Yamanaka: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006). (Pubitemid 44233629)
112. K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda and S. Yamanaka: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007). (Pubitemid 350138099)
113. J. Yu, M. A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J. L. Frane, S. Tian, J. Nie, G. A. Jonsdottir, V. Ruotti, R. Stewart, Slukvin, II and J. A. Thomson: Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
114. T. Aoi, K. Yae, M. Nakagawa, T. Ichisaka, K. Okita, K. Takahashi, T. Chiba and S. Yamanaka: Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321, 699-702 (2008).
115. H. Liu, F. Zhu, J. Yong, P. Zhang, P. Hou, H. Li, W. Jiang, J. Cai, M. Liu, K. Cui, X. Qu, T. Xiang, D. Lu, X. Chi, G. Gao, W. Ji, M. Ding and H. Deng: Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 3, 587-590 (2008).
116. J. Liao, C. Cui, S. Chen, J. Ren, J. Chen, Y. Gao, H. Li, N. Jia, L. Cheng, H. Xiao and L. Xiao: Generation of induced pluripotent stem cell lines from adult rat cells. Cell Stem Cell 4, 11-15 (2009).
117. M. Nakagawa, M. Koyanagi, K. Tanabe, K. Takahashi, T. Ichisaka, T. Aoi, K. Okita, Y. Mochiduki, N. Takizawa and S. Yamanaka: Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26, 101-106 (2008).
118. J. B. Kim, V. Sebastiano, G. Wu, M. J. Arauzo-Bravo, P. Sasse, L. Gentile, K. Ko, D. Ruau, M. Ehrich, D. van den Boom, J. Meyer, K. Hubner, C. Bernemann, C. Ortmeier, M. Zenke, B. K. Fleischmann, H. Zaehres and H. R. Scholer: Oct4-induced pluripotency in adult neural stem cells. Cell 136, 411-419 (2009).
119. M. Boiani, S. Eckardt, H. R. Scholer and K. J. McLaughlin: Oct4 distribution and level in mouse clones: consequences for pluripotency. Genes Dev. 16, 1209-1219 (2002). (Pubitemid 34553102)
120. M. C. Thomas and C. M. Chiang: The general transcription machinery and general cofactors. Crit Rev Biochem Mol Biol 41, 105-178 (2006).
121. S. Zwilling, A. Annweiler and T. Wirth: The POU domains of the Oct1 and Oct2 transcription factors mediate specific interaction with TBP. Nucleic Acids Res 22, 1655- 1662 (1994). (Pubitemid 24155822)
122. H. Nakshatri, P. Nakshatri and R. A. Currie: Interaction of Oct-1 with TFIIB. Implications for a novel response elicited through the proximal octamer site of the lipoprotein lipase promoter. J Biol Chem 270, 19613-19623 (1995).
123. T. G. Parslow, D. L. Blair, W. J. Murphy and D. K. Granner: Structure of the 5' ends of immunoglobulin genes: A novel conserved sequence. Proc Natl Acad Sci U S A 81, 2650- 2654 (1984). (Pubitemid 14109317)
124. K. Nelms and B. Van Ness: Identification of an octamerbinding site in the human kappa light-chain enhancer. Mol Cell Biol 10, 3843-3846 (1990).
125. L. M. Staudt and M. J. Lenardo: Immunoglobulin gene transcription. Annu Rev Immunol 9, 373-398 (1991).
126. L. Poellinger, B. K. Yoza and R. G. Roeder: Functional cooperativity between protein molecules bound at two distinct sequence elements of the immunoglobulin heavy-chain promoter. Nature 337, 573-576 (1989). (Pubitemid 19045545)
127. I. Kemler, E. Bucher, K. Seipel, M. M. Muller-Immergluck and W. Schaffner: Promoters with the octamer DNA motif (ATGCAAAT) can be ubiquitous or cell typespecific depending on binding affinity of the octamer site and Oct-factor concentration. Nucleic Acids Res 19, 237-242 (1991). (Pubitemid 21896964)
128. M. Strubin, J. W. Newell and P. Matthias: OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins. Cell 80, 497-506 (1995).
129. M. Salas and L. A. Eckhardt: Critical role for the Oct- 2/OCA-B partnership in Ig-secreting cells. J Immunol 171, 6589-6598 (2003). (Pubitemid 37532090)
130. J. Zheng, J. Huang, Y. Mao, S. Liu, X. Sun, X. Zhu, T. Ma, L. Zhang, J. Ji, Y. Zhang, C. C. Yin and X. Qiu: Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells. J Biol Chem 284, 13610-13619 (2009).
131. J. Huang, L. Zhang, T. Ma, P. Zhang and X. Qiu: Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse testis and epididymis. J Histochem Cytochem 57, 339-349 (2009).
132. X. Zhu, L. Wu, L. Zhang, P. Hao, S. Zhang, J. Huang, J. Zheng, Y. Liu, W. Li, Y. Zhang, C. Zhou, C. C. Yin and X. Qiu: Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells. Cell Mol Immunol 7, 279-286 (2010).
133. P. Wang and T. Jin: Oct-1 functions as a sensor for metabolic and stress signals. Islets 2, 46-48 (2010).
134. P. Wang, Q. Wang, J. Sun, J. Wu, H. Li, N. Zhang, Y. Huang, B. Su, R. K. Li, L. Liu, Y. Zhang, H. P. Elsholtz, J. Hu, H. Y. Gaisano and T. Jin: POU homeodomain protein Oct-1 functions as a sensor for cyclic AMP. J Biol Chem 284, 26456-26465 (2009).
135. A. Shakya, R. Cooksey, J. E. Cox, V. Wang, D. A. McClain and D. Tantin: Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity. Nat Cell Biol 11, 320-327 (2009).
136. D. Tantin, C. Schild-Poulter, V. Wang, R. J. Hache and P. A. Sharp: The octamer binding transcription factor Oct-1 is a stress sensor. Cancer Res 65, 10750-10758 (2005). (Pubitemid 41713343)
137. N. Bellance, L. Pabst, G. Allen, R. Rossignol and D. Nagrath: Oncosecretomics coupled to bioenergetics identifies alpha-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: Differential expression of c-Myc, Oct1 and KLF4 coordinates metabolic changes. Biochim Biophys Acta 1817, 2060-2071 (2012).
138. H. Zhao, S. Jin, F. Fan, W. Fan, T. Tong and Q. Zhan: Activation of the Transcription Factor Oct-1 in Response to DNA Damage. Cancer Res 60, 6276-6280 (2000).
139. C. Schild-Poulter, A. Shih, D. Tantin, N. C. Yarymowich, S. Soubeyrand, P. A. Sharp and R. J. Hache: DNA-PK phosphorylation sites on Oct-1 promote cell survival following DNA damage. Oncogene 26, 3980-3988 (2007). (Pubitemid 46884292)
140. C. Schild-Poulter, A. Shih, N. C. Yarymowich and R. J. Hache: Down-regulation of histone H2B by DNAdependent protein kinase in response to DNA damage through modulation of octamer transcription factor 1. Cancer Res 63, 7197-7205 (2003). (Pubitemid 37413458)
141. J. Kang, M. Gemberling, M. Nakamura, F. G. Whitby, H. Handa, W. G. Fairbrother and D. Tantin: A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress. Genes Dev 23, 208-222 (2009).
142. P. Winklehner-Jennewein, S. Geymayer, J. Lechner, T. Welte, L. Hansson, S. Geley and W. Doppler: A distal enhancer region in the human beta-casein gene mediates the response to prolactin and glucocorticoid hormones. Gene 217, 127-139 (1998). (Pubitemid 28427315)
143. M. A. Groenen, R. J. Dijkhof, J. J. van der Poel, R. van Diggelen and E. Verstege: Multiple octamer binding sites in the promoter region of the bovine alpha s2-casein gene. Nucleic Acids Res 20, 4311-4318 (1992).
144. W. Mandemakers, R. Zwart, M. Jaegle, E. Walbeehm, P. Visser, F. Grosveld and D. Meijer: A distal Schwann cell-specific enhancer mediates axonal regulation of the Oct-6 transcription factor during peripheral nerve development and regeneration. EMBO J 19, 2992-3003 (2000). (Pubitemid 30386770)
145. M. Jaegle, M. Ghazvini, W. Mandemakers, M. PIIrsoo, S. Driegen, F. Levavasseur, S. Raghoenath, F. Grosveld and D. Meijer: The POU proteins Brn-2 and Oct- 6 share important functions in Schwann cell development. Genes Dev 17, 1380-1391 (2003). (Pubitemid 36666007)
146. N. B. Jagalur, M. Ghazvini, W. Mandemakers, S. Driegen, A. Maas, E. A. Jones, M. Jaegle, F. Grosveld, J. Svaren and D. Meijer: Functional dissection of the Oct6 Schwann cell enhancer reveals an essential role for dimeric Sox10 binding. J Neurosci 31, 8585-8594 (2011).
147. J. Ghislain and P. Charnay: Control of myelination in Schwann cells: A Krox20 cis-regulatory element integrates Oct6, Brn2 and Sox10 activities. EMBO Rep 7, 52-58 (2006).
148. J. Svaren and D. Meijer: The molecular machinery of myelin gene transcription in Schwann cells. Glia 56, 1541- 1551 (2008).
149. Z. P. Pang, N. Yang, T. Vierbuchen, A. Ostermeier, D. R. Fuentes, T. Q. Yang, A. Citri, V. Sebastiano, S. Marro, T. C. Sudhof and M. Wernig: Induction of human neuronal cells by defined transcription factors. Nature 476, 220-223 (2011).
150. Y. Sugitani, S. Nakai, O. Minowa, M. Nishi, K. Jishage, H. Kawano, K. Mori, M. Ogawa and T. Noda: Brn-1 and Brn-2 share crucial roles in the production and positioning of mouse neocortical neurons. Genes Dev 16, 1760-1765 (2002). (Pubitemid 34803892)
151. T. Shimazaki, Y. Arsenijevic, A. K. Ryan, M. G. Rosenfeld and S. Weiss: A role for the POU-III transcription factor Brn-4 in the regulation of striatal neuron precursor differentiation. EMBO J 18, 444-456 (1999). (Pubitemid 29041952)
152. J. Shi, G. Jin, H. Zhu, M. Tian, X. Zhang, J. Qin and X. Tan: The role of Brn-4 in the regulation of neural stem cell differentiation into neurons. Neurosci Res 67, 8-17 (2010).
153. B. Andersen, M. D. Schonemann, S. E. Flynn, R. V. Pearse 2nd, H. Singh and M. G. Rosenfeld: Skn-1a and Skn-1i: two functionally distinct Oct-2-related factors expressed in epidermis. Science 260, 78-82 (1993). (Pubitemid 23122747)
154. J. Hildesheim, U. Kuhn, C. L. Yee, R. A. Foster, K. B. Yancey and J. C. Vogel: The hSkn-1a POU transcription factor enhances epidermal stratification by promoting keratinocyte proliferation. J Cell Sci 114, 1913-1923 (2001). (Pubitemid 32530046)
155. T. M. Sugihara, E. I. Kudryavtseva, V. Kumar, J. J. Horridge and B. Andersen: J The POU domain factor Skin- 1a represses the keratin 14 promoter independent of DNA binding. A possible role for interactions between Skn-1a and CREB-binding protein/p300. Biol Chem 276, 33036- 33044 (2001).
156. C. H. Botting and R. T. Hay: Characterisation of the adenovirus preterminal protein and its interaction with the POU homeodomain of NFIII (Oct-1). Nucleic Acids Res 27, 2799-2805 (1999). (Pubitemid 29306580)
157. S. Belikov, P. H. Holmqvist, C. Astrand and O. Wrange: Nuclear factor 1 and octamer transcription factor 1 binding preset the chromatin structure of the mouse mammary tumor virus promoter for hormone induction. J Biol Chem 279, 49857-49867 (2004). (Pubitemid 39577792)
158. Y. Liu, W. Gong, C. C. Huang, W. Herr and X. Cheng: Crystal structure of the conserved core of the herpes simplex virus transcriptional regulatory protein VP16. Genes Dev 13, 1692-1703 (1999). (Pubitemid 29325874)
159. M. L. Nogueira, V. E. Wang, D. Tantin, P. A. Sharp and T. M. Kristie: Herpes simplex virus infections are arrested in Oct-1-deficient cells. Proc Natl Acad Sci U S A 101, 1473-1478 (2004). (Pubitemid 38234179)
160. A. R. Robinson, S. S. Kwek, S. R. Hagemeier, C. K. Wille and S. C. Kenney: Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency. J Virol 85, 8940-8953 (2011).
161. T. Mesplede, M. L. Island, N. Christeff, F. Petek, J. Doly and S. Navarro: The POU transcription factor Oct-1 represses virus-induced interferon A gene expression. Mol Cell Biol 25, 8717-8731 (2005). (Pubitemid 41369189)
162. R. Almeida, J. Almeida, M. Shoshkes, N. Mendes, P. Mesquita, E. Silva, I. Van Seuningen, C. A. Reis, F. Santos-Silva and L. David: OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells. J Pathol 207, 396-401 (2005). (Pubitemid 43025687)
163. T. Jin, D. R. Branch, X. Zhang, S. Qi, B. Youngson and P. E. Goss: Examination of POU homeobox gene expression in human breast cancer cells. Int J Cancer 81, 104-112 (1999). (Pubitemid 29124204)
164. D. Obinata, K. Takayama, T. Urano, T. Murata, J. Kumagai, T. Fujimura, K. Ikeda, K. Horie-Inoue, Y. Homma, Y. Ouchi, S. Takahashi and S. Inoue: Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int J Cancer 130, 1021-1028 (2012).
165. C. Zhou, Y. Tong, K. Wawrowsky, S. Bannykh, I. Donangelo and S. Melmed: Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors. Endocr Relat Cancer 15, 817-831 (2008).
166. X. F. Qin, Y. Luo, H. Suh, J. Wayne, Z. Misulovin, R. G. Roeder and M. C. Nussenzweig: Transformation by homeobox genes can be mediated by selective transcriptional repression. EMBO J 13, 5967-5976 (1994).
167. M. C. Ng, V. K. Lam, C. H. Tam, A. W. Chan, W. Y. So, R. C. Ma, B. C. Zee, M. M. Waye, W. W. Mak, C. Hu, C. R. Wang, P. C. Tong, W. P. Jia and J. C. Chan: Association of the POU class 2 homeobox 1 gene (POU2F1) with susceptibility to Type 2 diabetes in Chinese populations. Diabet Med 27, 1443-1449 (2010).
168. J. Theil, H. Laumen, T. Marafioti, M. Hummel, G. Lenz, T. Wirth and H. Stein: Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood 97, 3191-3196 (2001).
169. D. Re, M. Muschen, T. Ahmadi, C. Wickenhauser, A. Staratschek-Jox, U. Holtick, V. Diehl and J. Wolf: Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res 61, 2080-2084 (2001). (Pubitemid 32692030)
170. D. L. Di Bartolo, E. Hyjek, S. Keller, I. Guasparri, H. Deng, R. Sun, A. Chadburn, D. M. Knowles and E. Cesarman: Role of defective Oct-2 and OCA-B expression in immunoglobulin production and Kaposi's sarcoma-associated herpesvirus lytic reactivation in primary effusion lymphoma. J Virol 83, 4308-4315 (2009).
171. P. Browne, K. Petrosyan, A. Hernandez and J. A. Chan: The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 120, 767-777 (2003). (Pubitemid 37339686)
172. S. Gidekel, G. Pizov, Y. Bergman and E. Pikarsky: Oct- 3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4, 361-370 (2003). (Pubitemid 37491097)
173. J. de Jong and L. H. Looijenga: Stem Cell Marker OCT3/4 in Tumor Biology and Germ Cell Tumor Diagnostics: History and Future. Crit Rev Oncog 12, 171-203 (2006). (Pubitemid 46524130)
174. M. Monk and C. Holding: Human embryonic genes re-expressed in cancer cells. Oncogene 20, 8085-8091 (2001). (Pubitemid 34028332)
175. Y. Atlasi, S. J. Mowla, S. A. Ziaee and A. R. Bahrami: OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 120, 1598-1602 (2007). (Pubitemid 46355399)
176. Z. Chen, W. R. Xu, H. Qian, W. Zhu, X. F. Bu, S. Wang, Y. M. Yan, F. Mao, H. B. Gu, H. L. Cao and X. J. Xu: Oct4, a novel marker for human gastric cancer. J Surg Oncol 99, 414-419 (2009).
177. K. Iki and P. M. Pour: Expression of Oct4, a stem cell marker, in the hamster pancreatic cancer model. Pancreatology 6, 406-413 (2006). (Pubitemid 44329087)
178. G. Karoubi, M. Gugger, R. Schmid and A. Dutly: OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interact Cardiovasc Thorac Surg 8, 393-397 (2009).
179. S. Saigusa, K. Tanaka, Y. Toiyama, T. Yokoe, Y. Okugawa, Y. Ioue, C. Miki and M. Kusunoki: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16, 3488-3498 (2009).
180. K. Xu, Z. Zhu and F. Zeng: Expression and significance of Oct4 in bladder cancer. J Huazhong Univ Sci Technolog Med Sci 27, 675-677 (2007).
181. Z. Zhu, J. Wen, X. Zheng, D. Wang, Q. Wang and C. Fan: Expression of transcription factor Oct4 in bladder cancer cell line T24 and its effects on the biological characteristics of the cells. J Huazhong Univ Sci Technolog Med Sci 29, 73-76 (2009).
182. P. Wang, D. R. Branch, M. Bali, G. A. Schultz, P. E. Goss and T. Jin: The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells. Biochem J. 375, 199-205 (2003). (Pubitemid 37255396)
183. S. W. McLeskey, J. Kurebayashi, S. F. Honig, J. Zwiebel, M. E. Lippman, R. B. Dickson and F. G. Kern: Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 53, 2168-2177 (1993). (Pubitemid 23145744)
184. K. Hochedlinger, Y. Yamada, C. Beard and R. Jaenisch: Ectopic Expression of Blocks Progenitor-Cell Differentiation and Causes Dysplasia in Epithelial Tissues. Cell 121, 465-477 (2005). (Pubitemid 40692305)
185. T. Mueller, J. Luetzkendorf, K. Nerger, H. J. Schmoll and L. P. Mueller: Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells. Cell Mol Life Sci 66, 495-503 (2009).
186. T. Cantz, G. Key, M. Bleidissel, L. Gentile, D. W. Han, A. Brenne and H. R. Scholer: Absence of OCT4 expression in somatic tumor cell lines. Stem Cells 26, 692- 697 (2008).
187. G. Suo, J. Han, X. Wang, J. Zhang, Y. Zhao, Y. Zhao and J. Dai: Oct4 pseudogenes are transcribed in cancers. Biochem. Biophys. Res. Commun. 337, 1047 (2005).
188. A. L. Cook and R. A. Sturm: POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res 21, 611-626 (2008).
189. G. M. Boyle, S. L. Woods, V. F. Bonazzi, M. S. Stark, E. Hacker, L. G. Aoude, K. Dutton-Regester, A. L. Cook, R. A. Sturm and N. K. Hayward: Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res 24, 525-537 (2011).
190. I. Berlin, L. Denat, A. L. Steunou, I. Puig, D. Champeval, S. Colombo, K. Roberts, E. Bonvin, Y. Bourgeois, I. Davidson, V. Delmas, L. Nieto, C. R. Goding and L. Larue: Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation. Mol Cell Biol 32, 1237-1247 (2012).
191. A. E. Thurber, G. Douglas, E. C. Sturm, S. E. Zabierowski, D. J. Smit, S. N. Ramakrishnan, E. Hacker, J. H. Leonard, M. Herlyn and R. A. Sturm: Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30, 3036-3048 (2011).
192. H. K. Lee, M. H. Song, M. Kang, J. T. Lee, K. A. Kong, S. J. Choi, K. Y. Lee, H. Venselaar, G. Vriend, W. S. Lee, H. J. Park, T. K. Kwon, J. Bok and U. K. Kim: Clinical and molecular characterizations of novel POU3F4 mutations reveal that DFN3 is due to null function of POU3F4 protein. Physiol Genomics 39, 195-201 (2009).
193. T. M. Coate, S. Raft, X. Zhao, A. K. Ryan, E. B. Crenshaw 3rd and M. W. Kelley: Otic mesenchyme cells regulate spiral ganglion axon fasciculation through a Pou3f4/EphA4 signaling pathway. Neuron 73, 49-63 (2012).
194. M. H. Song, S. Y. Choi, L. Wu, S. K. Oh, H. K. Lee, D. J. Lee, D. B. Shim, J. Y. Choi, U. K. Kim and J. Bok: Pou3f4 deficiency causes defects in otic fibrocytes and stria vascularis by different mechanisms. Biochem Biophys Res Commun 404, 528-533 (2011).
195. D. Phippard, L. Lu, D. Lee, J. C. Saunders and E. B. Crenshaw 3rd: Targeted mutagenesis of the POU-domain gene Brn4/Pou3f4 causes developmental defects in the inner ear. J Neurosci 19, 5980-5989 (1999). (Pubitemid 29327932)
196. Y. Enomoto, K. Enomoto, T. Kitamura and T. Kanda: Keratinocyte-specific POU transcription factor hSkn-1a represses the growth of cervical cancer cell lines. Oncogene 23, 5014-5022 (2004). (Pubitemid 38938734)
197. Z. Zhang, P. C. Huettner, L. Nguyen, M. Bidder, M. C. Funk, J. Li and J. S. Rader: Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene 25, 5436-5445 (2006). (Pubitemid 44330286)